
City Therapeutics Inc.
CTYHealthcare|Biotechnology|US
$18.25
+1.18 (+6.91%)
Upcoming Data Readouts (70)
Nov 2026
Est. completion
NAPlantar Fasciitis of Both Feet
Video-Based Versus Physician-Led Exercise Training for Plantar Fasciitis
NCT07628218n=300
Nov 2026
Est. completion
NAPain, Postoperative
Comparison of the Rhomboid Intercostal Block and Serratus Posterior Superior Intercostal Plane Block
NCT07650877n=90
Nov 2026
Est. completion
Hematopoietic and Lymphatic System Neoplasm
On the BRINK: PhotoBiomodulation (PBM) for Mucositis in Patients Undergoing Allogeneic Hematopoietic Stem Cell TRansplant (HSCT) - Implementing the Evidence & Discovering New Knowledge
NCT06625619n=6
Nov 2026
Est. completion
Dec 2026
Est. completion
NADyssynergic Defaecation
Efficacy of Cognitive Behavioral Therapy Administered in Patients With Dyssynergic Defecation
NCT07488442n=26
Dec 2026
Est. completion
Dec 2026
Est. completion
NAUnruptured Intracranial Aneurysm
INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)
NCT07089862n=2,500
Dec 2026
Est. completion
Breast Cancer, Metastatic
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment
NCT06663787n=50
Jan 2027
Est. completion
P2Mantle Cell Lymphoma
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
NCT06572618n=27
Jan 2027
Est. completion
P2Smoldering Plasma Cell Myeloma
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
NCT05014646n=27
Jan 2027
Est. completion
NALung Carcinoma
Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer
NCT05384769n=108
Jan 2027
Est. completion
P2Anatomic Stage IV Breast Cancer AJCC v8
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
NCT06860815n=11
Feb 2027
Est. completion
P1P2Blastoid Variant Mantle Cell Lymphoma
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
NCT05861050n=50
Feb 2027
Est. completion
Feb 2027
Est. completion
P1Hematopoietic and Lymphoid Cell Neoplasm
CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant
NCT03922035n=36
Mar 2027
Est. completion
P1Anatomic Stage IV Breast Cancer AJCC v8
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
NCT05081492n=9
Mar 2027
Est. completion
P2Lung Non-Small Cell Carcinoma
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
NCT06014827n=32
Mar 2027
Est. completion
NAOverweight and/or Obesity
iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss
NCT07237750n=216
Apr 2027
Est. completion
NAAcute Anterior Shoulder Dislocation
FARES Versus Traction-Countertraction for Acute Anterior Shoulder Dislocation
NCT07757594n=60
Apr 2027
Est. completion
NAOpioid Dependence
The MOUD Plus Pilot: Counseling and Peer Support to Support Retention for Medically Complex Patients With Opioid Use Disorder Seen In Primary Care
NCT06837662n=70
Awaiting Results (20)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
NA
Implementation Study With Embedded RCT of a Digital System of Parenting Support Within Government Services in South Africa
NCT07814261Oct 2026
Post-Induction Low Cardiac Output Syndrome in Coronary Artery Bypass Graft Surgery
NCT07810621Aug 2026
The Effect of Factors Affecting Bone Mineral Density Measurement Results on Osteoporosis Diagnosis and Treatment Decision
NCT07812402Apr 2026
NA
First-in-human Trial of Home Brain Pressure Measured Using Kitea ICP Sensor, Placed During Hydrocephalus Shunt Surgery.
NCT06402786Mar 2026
P2
COVID-19 Rapid Test-to-Treat With African American Churches (Faithful Response II)
NCT07450209Sep 2025
NA
Effects of Relaxation, Mindfulness, and Breathing Therapy on Alarm Fatigue and Psychological Well-being in Intensive Care Nurses
NCT07124364Aug 2025
NA
Cutaneous Silent Period-Based Comparison of DRG-PRF and TFESI in Lumbar Radicular Pain
NCT07097532Recent Press Releases
Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
Nov 4, 2026 · GlobeNewsWire
City Therapeutics to Present at Upcoming November Investor Conferences
Nov 3, 2026 · GlobeNewsWire
City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Oct 19, 2026 · GlobeNewsWire
City Therapeutics Announces Pricing of Upsized Initial Public Offering
Oct 15, 2026 · GlobeNewsWire